Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 15, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Colin Bristow Maintained (ALXO) at Strong Buy with Decreased Target to $29 on, Mar 15th, 2023
Colin Bristow of UBS, Maintained "ALX Oncology Holdings Inc." (ALXO) at Strong Buy with Decreased Target from $31 to $29 on, Mar 15th, 2023.
Colin has made no other calls on ALXO in the last 4 months.
There are 2 other peers that have a rating on ALXO. Out of the 2 peers that are also analyzing ALXO, 0 agree with Colin's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Colin
- Swayampakula Ramakanth of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $30 on, Friday, March 10th, 2023
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $34 on, Friday, March 10th, 2023
